



Date: 14<sup>th</sup> September, 2020.

To,  
BSE Limited,  
Listing Compliance Department,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir/Madam,

Ref: Script Id "BAJAJHCARE", Script Code "539872".

Sub: Disclosure under regulation 30 of the SEBI (Listing Obligation Disclosure Requirements) Regulation, 2015 (Outcome of Board Meeting).

We hereby inform you that the Board of Directors at their meeting held today i.e. 14<sup>th</sup> September, 2020 has inter-alia considered and approved the following:

- Unaudited Financial results for the quarter ended on 30<sup>th</sup> June, 2020 along with Limited Review Report.  
The copy of approved financial results along with the Limited Review Report are enclosed herewith.
- Re-appointment of Mr. Hemant Karnik (DIN 07377151) for Second Term of Five years as Independent Directors on the Board of the Company.
- Re-appointment of Mr. Ram Banarse (DIN 07405486) for Second Term of Five years as Independent Directors on the Board of the Company.
- Under Section 139 of the Companies Act, 2013 and rules made thereunder, the board of director has recommended the appointment of M/s Chaturvedi & Agarwal (FRN 101717W) for a period of five years from the conclusion of 27<sup>th</sup> Annual General Meeting till the conclusion of 32<sup>nd</sup> Annual General Meeting of the Company, subject to approval of shareholders at ensuing Annual General Meeting, under rotation of Auditor.

Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligation Disclosure Requirements) Regulation, 2015, the details required are enclosed as Annexure -I for appointment and reappointment of Directors.

We wish to inform you that Board Meeting commenced today at 4.00 p.m. and concluded at 6.30 p.m.

You are requested to take the same on record.

Thanking you.

Yours faithfully,

For and behalf of Board of Directors of  
Bajaj Healthcare Limited

Aakash Keshari  
Company Secretary



Encl: As above

**BAJAJ HEALTHCARE LTD**

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

Annexure-I

Brief profiles:

Sr. No.	Details of Event(s) that Needs to be provided	Mr. Hemant Karnik	Mr. Ram Banarse	Mr. Avinash Dalal
1.	Reason for Change Viz. Appointment	Re-appointment as an Independent Director for second term (subject to shareholders approval)	Re-appointment as an Independent Director for second term (subject to shareholders approval)	Confirm appoint after attaining 75 years of Age i.e. with effect from 5 <sup>th</sup> April, 2021 (subject to shareholders approval)
2.	Date of Appointment & Term of Appointment	Re-appointment w.e.f. 07 <sup>th</sup> January, 2021 for second term as Independent Director	Re-appointment w.e.f. 13 <sup>th</sup> January, 2021 for second term as Independent Director.	Continue as Independent Director after attaining age of 75 years w.e.f. 15 April, 2020.
3.	Brief profile	Mr. Hemant R. Karnik is a Non-Executive Independent Director of our Company. He has completed Master's in Commerce from Mumbai University. Mr. Karnik is a financial professional with 32 years of experience spanning functions of anking & Corporate Finance. He is retired from the position of Head-SMEs & GM-Branches at The Saraswat Co-op Bank Ltd. During his career, this helped him to earn eight merit promotion and numerous awards.	Mr. Ram B. Banarse is a Non-Executive Independent Director of our Company. He has completed Bachelor of Pharmacy, M.Sc. in Clinical Research & Regulatory Affair and Bachelor of Law. He is a proficient Pharmaceutical professional with 35 years of industry experience in manufacturing, quality control and regulations. Mr. Banarse is a retired Asst. Commissioner with additional charges as Jt. Commissioner at Food and Drugs Administrator (FDA) Mumbai.	Mr. Avinash Dalal, aged 63 year, is Non- Executive Independent Director of our Company. He has completed Diploma in Business Management (DBM). He is a founder of All India Micro Small Medium Enterprises and also member of various association such as Association of Small & Medium Chemical Manufacturers, Federation of Association of Maharashtra (FAM- Maharashtra) Maharashtra Chamber of Commerce, Industry and agriculture (MCCIA), etc. He was also a director in Dena Bank from the year 2000 to 2003 as representative of Shareholders
4.	Disclosure of relationships between directors ( in case of appointment of a director)	Not related to any Director of the Company nor disqualified to act as Director by any regulatory	Not related to any Director of the Company nor disqualified to act as Director by any regulatory	Not related to any Director of the Company nor disqualified to act as Director by any regulatory



**PARESH  
RAKESH**  
  
**ASSOCIATES**  
Chartered Accountants

**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to  
The Board of Directors  
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Paresh Rakesh & Associates**  
**Chartered Accountants**

FRN: 119728W



**Rakesh Chaturvedi**

M. no: 102075

UDIN: 20102075AAAAGO5188



**Date: 14<sup>th</sup> September 2020**

**Place: Mumbai**

**BAJAJ HEALTHCARE LIMITED**  
( CIN No. : L99999MH1993PLC072892 )

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AS ON 30TH JUNE, 2020**

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
<b>I. Revenue from operations</b>	13,983.32	11,849.65	9,169.38	41,000.84
<b>II. Other Income</b>	90.17	286.09	41.17	317.91
<b>III. Total Revenue (I+II)</b>	<b>14,073.49</b>	<b>12,135.74</b>	<b>9,210.55</b>	<b>41,318.74</b>
<b>IV. Expenses</b>				
(a) Cost of materials consumed (Including Other Direct Expenses)	10,388.39	8,964.99	7,007.71	32,027.10
(b) Changes in Inventories of Finished Good	-375.67	-367.73	284.89	-508.76
(c) Employee benefits expense	798.73	734.82	635.00	2,817.83
(d) Finance Costs	204.81	139.34	182.67	644.93
(d) Depreciation and amortisation expense	376.47	337.79	294.15	1,212.33
(e) Other expenses	637.30	534.34	344.54	1,519.28
<b>Total Expenses</b>	<b>12,030.04</b>	<b>10,343.55</b>	<b>8,748.96</b>	<b>37,712.73</b>
<b>V. Profit before Exceptional Items</b>	<b>2,043.46</b>	<b>1,792.19</b>	<b>461.59</b>	<b>3,606.02</b>
VI. Exceptional items	-	-	-	-
<b>VII. Profit Before Tax</b>	<b>2,043.46</b>	<b>1,792.19</b>	<b>461.59</b>	<b>3,606.02</b>
<b>VIII. Tax Expense</b>				
(a) Current tax	573.40	370.00	140.00	910.00
(b) Deffered Tax	-59.10	163.30	-2.38	148.91
(c) Earlier Years	-	2.62	-	23.44
<b>Total Tax Expenses</b>	<b>514.30</b>	<b>535.92</b>	<b>137.62</b>	<b>1,082.35</b>
<b>IX. Profit (Loss) for the Period</b>	<b>1,529.16</b>	<b>1,256.28</b>	<b>323.96</b>	<b>2,523.67</b>
<b>X. Other comprehensive Income</b>				
(i) Items that will not be reclassified to profit or loss	-	-25.51	-	-25.51
(ii) Income tax relating to items that will not be reclassified to profit or loss				
(i) Items that will be reclassified to profit or loss				
(ii) Income tax relating to items that will be reclassified to profit or loss				
<b>Total Comprehensive Income for the Period</b>	<b>1,529.16</b>	<b>1,230.77</b>	<b>323.96</b>	<b>2,498.16</b>
<b>XI. Paid-up Equity Share Capital (Face Value Rs. 10/-)</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>
<b>XII. Other Equity excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>16,405.88</b>
<b>XIII. EPS (Not Annualised)</b>				
(a) Basic	11.08	6.96	2.35	18.29
(b) Diluted	11.08	6.96	2.35	18.29

FOR BAJAJ HEALTHCARE LTD.

DIRECTOR

**Note :**

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at its meetings held on September 14, 2020.
- b) As the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019. Ind-AS is applicable from 1st April, 2020.
- c) The company has first time adopted Indian Accounting Standard ("Ind AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015 from April 1, 2020. The above financial results have been prepared in accordance with principles as laid down in Ind AS-34 - Interim Financial Reporting.
- d) The Company has first time adopted Indian Accounting Standard ("Ind AS"), accordingly the Company had prepared comparative figures of quarter ended 30<sup>th</sup> June 2019 and 31<sup>st</sup> March 2020 as given above by the management after exercising necessary due diligence to ensure financial results reflects true and fair view of Company's affairs in Indian Accounting Standard ("Ind AS").
- e) The financial results for the quarter ended 30<sup>th</sup> June 2020 have been subjected to limited review by the statutory auditors of the Company. The comparative figures of quarter ended 30<sup>th</sup> June 2019 and 31<sup>st</sup> March 2020 and Year End figures for 31<sup>st</sup> March 2020 are not subject to Review of the Statutory Auditors.

(Rs. in Lakhs)

Particulars	Profit Reconciliation			Reserves Reconciliation	
	Quarter ended March 31, 2020	Quarter ended June 30, 2019	Year Ended March 31, 2020	Year Ended March 31, 2020	Year Ended March 31, 2020
Net profit after tax/ Reserve reported under previous GAAP	960.05	324.18	2249.98		13780.70
Adjustments increasing/(decreasing) net profit/ Reserve as reported in the previous GAAP	391.34	-0.29	360.89		-139.96
Adjustments in Deffered Tax	-95.12	0.08	-87.20		38.85
Fair Value/ Revalued figure considered as Deemed Cost for Property Plant and Equipment - Land as on 01st April 2019					2751.79
<b>Net Profit after tax/ Reserve reported under Ind AS</b>	<b>1256.28</b>	<b>323.96</b>	<b>2523.67</b>		<b>16431.39</b>
Other Comprehensive Income / Loss (Net of Tax)	-25.51	-	-25.51		-25.51
<b>Total Comprehensive Income (after tax)/ Reserves as reported under Ind AS</b>	<b>1230.77</b>	<b>323.96</b>	<b>2498.16</b>		<b>16405.88</b>

- g) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.
- h) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to confirm with current period classification.

By Order of the Board  
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Managing Director



Date: 14th September 2020  
Place: Thane

**BAJAJ HEALTHCARE LIMITED**

( CIN No. : L99999MH1993PLC072892 )

**REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 30th JUNE, 2020**

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
A	<b>Segment Revenue ( Excluding Intersegment Revenue)</b>				
	Bulk Drugs	12568.26	11254.49	8674.87	38607.49
	Formulations	1415.06	595.16	494.51	2464.31
	<b>Total</b>	<b>13,983.32</b>	<b>11,849.65</b>	<b>9,169.38</b>	<b>41,071.80</b>
	<b>Segment Revenue ( Intersegment Revenue)</b>				
	Bulk Drugs	783.46	617.67	563.34	2,108.98
	Formulations	3.54	23.78	31.06	86.18
	<b>Total</b>	<b>787.01</b>	<b>641.44</b>	<b>594.40</b>	<b>2,195.15</b>
	<b>Gross Segment Revenue ( Including Intersegment Revenue)</b>				
	Bulk Drugs	13351.73	11872.16	9238.21	40716.46
	Formulations	1418.60	618.94	525.58	2550.49
	<b>Total</b>	<b>14,770.33</b>	<b>12,491.10</b>	<b>9,763.78</b>	<b>43,266.95</b>
B	<b>II. Segment Results</b>				
	<b>Profit / (Loss) Before Tax &amp; Finance Cost</b>				
	Bulk Drugs	2,746.60	2,951.39	1,090.66	6,330.53
	Formulations	127.05	-119.68	-102.15	-224.92
	<b>Total</b>	<b>2,873.65</b>	<b>2,831.71</b>	<b>988.51</b>	<b>6,105.61</b>
	<b>Less : Interest</b>	<b>204.81</b>	<b>139.34</b>	<b>182.67</b>	<b>644.93</b>
<b>Other Unallocable Expenditure (Net)</b>	<b>625.38</b>	<b>900.18</b>	<b>344.25</b>	<b>1,854.66</b>	
<b>Total Profit Before Tax</b>	<b>2,043.46</b>	<b>1,792.19</b>	<b>461.59</b>	<b>3,606.02</b>	
C	<b>I. Segment Assets</b>				
	Bulk Drugs	37,912.63	31,563.91	27,234.94	31,563.91
	Formulations	2,547.92	3,096.65	1,991.65	3,096.65
	Others	500.31	500.31	500.31	500.31
	<b>Total</b>	<b>40,960.86</b>	<b>35,160.86</b>	<b>29,726.89</b>	<b>35,160.86</b>
	<b>II. Segment Liabilities</b>				
	Bulk Drugs	20,096.23	15,489.68	12,552.71	15,489.68
	Formulations	591.27	584.70	582.17	584.70
	Others	958.62	1,300.67	980.40	1,300.67
	<b>Total</b>	<b>21,646.12</b>	<b>17,375.06</b>	<b>14,115.28</b>	<b>17,375.06</b>
	<b>Total Capital Employed</b>	<b>19,314.74</b>	<b>17,785.80</b>	<b>15,611.61</b>	<b>17,785.80</b>
	<b>Total ( II+III)</b>	<b>40,960.86</b>	<b>35,160.86</b>	<b>29,726.89</b>	<b>35,160.86</b>

By Order of the Board  
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Managing Director

Place : Thane  
Date: 14th September 2020